M. King Robson talks again about women and the need for the pink pill
Michelle King Robson testified for Flibanserin, and about hypoactive sexual desire disorder (HSDD) when Flibanserin was aiming for FDA approval a year ago, on June 18, 2013. Flibanserin, more commonly called “the little pink pill”, is the first drug intended to treat sexual dysfunction in women.
Michelle has been fighting the battle against female sexual dysfunction for years.
Some of her reasons are personal. At the age of 42 she had a complete hysterectomy because that was her doctor's advice and she trusted her doctor.
She hadn't been warned what awaited her after the hysterectomy. Michelle says, "I was like a different person." It took several years but she was fortunate enough to find help to come back to health once more. She says, "I got well, and then ... I got mad."
Some of Michelle's reasons for fighting the battle are out of concern for other women, the men in their lives and their families. She dedicated her life to protecting other women from going through such suffering. She created EmpowHER. She has become an advocate for women in every arena she can reach.
"Women are having sexual health struggles and yet so often they aren't believed or listened to. Some are headed for divorce court because sex is non-existent for them and their relationships have tanked," said.
"We're told, 'It's all in your heads,' but that's just not true! Just try to put yourself in the shoes of a woman who's having painful sex and then tell me there's no sexual dysfunction. Or, the poor woman who has zero desire like I did because she was given a complete hysterectomy and never was given hormonal options to help her libido along with so many other health issues that come from having little to no hormones."
When Flibanserin was being considered by the FDA last year, Michelle had polls on her website EmpowHER about the pink pill. The poll results showed that more than 8,000 women wanted a pink pill. They wanted something to help to correct sexual dysfunction.